Basic Mobic Information

• INN (International Nonproprietary Name): Meloxicam
• Brand Names Available In Canada (English): Mobic and generics (marketed under the INN meloxicam)
• ATC Code: M01AC06
• Forms & Dosages: Oral Tablets 7.5 mg and 15 mg; Oral Suspension 7.5 mg/5 mL; Capsules (5 mg, 10 mg noted internationally); IV single‑use vials 30 mg.
• Manufacturers In Canada (English): Boehringer Ingelheim (original developer) and multiple generic suppliers (various local registration and branding).
• Registration Status In Canada (English): Listed as a prescription medicine in Canada; generics and branded formulations are registered with Health Canada (DINs assigned per product).
• OTC / Rx Classification: Prescription-Only (Rx) in Canada and other major markets.

Key Findings From Recent Trials — Research-First Synthesis

Worried about safety in older relatives taking long‑term NSAIDs?

Recent studies from 2022–2025 focused on real‑world safety and comparative effectiveness for meloxicam and other oxicams.

Large pharmacoepidemiology cohorts in Canada and Europe examined cardiovascular, gastrointestinal and renal outcomes in older adults on chronic NSAID therapy.

Overall findings place meloxicam in a class‑level risk profile similar to other long‑acting oxicams.

Randomised trials and meta‑analyses through 2024 reported analgesia for osteoarthritis and rheumatoid arthritis that is non‑inferior to some commonly used NSAIDs such as naproxen or ibuprofen.

Meloxicam shows slightly greater COX‑2 preferential activity than non‑selective NSAIDs at therapeutic doses, which can translate into mixed gastrointestinal benefit but does not remove cardiovascular caution.

Canadian hospital post‑market surveillance flagged renal adverse events in frail elderly patients on multiple medications.

Regulatory authorities continue to recommend the lowest effective dose and close monitoring for chronic users.

Practical implication for prescribers and pharmacists is to favour starting at 7.5 mg daily for older adults and to reassess ongoing need regularly.

Main Outcomes

Trials show meloxicam provides effective once‑daily pain control in osteoarthritis and chronic inflammatory arthritis at 7.5–15 mg daily.

Comparative effectiveness versus naproxen and ibuprofen is generally similar for symptom relief in trials through 2024.

Long half‑life supports adherence compared with short‑acting NSAIDs that require multiple daily doses.

Real‑world cohorts reported measurable GI and CV signals consistent with NSAID class effects rather than drug‑specific unique safety advantages.

Safety Observations

Surveillance data emphasise renal risks in the elderly, particularly when combined with diuretics, ACE inhibitors or ARBs.

There remains a class‑level cardiovascular signal; use in patients with CV risk requires individual risk–benefit discussion.

Gastrointestinal bleeding and peptic ulceration continue to be observed in long‑term users, especially without gastroprotection in high‑risk patients.

Clinical Mechanism Of Action

What does meloxicam do and why does dosing matter?

Meloxicam is an oxicam non‑steroidal anti‑inflammatory drug that reduces pain, swelling and fever by inhibiting cyclooxygenase enzymes involved in prostaglandin production.

At a simple level, it lowers the chemical signals that make joints sore and inflamed.

Scientifically, meloxicam preferentially inhibits COX‑2 over COX‑1 at therapeutic doses, which can lessen some COX‑1 mediated gastric effects compared with non‑selective NSAIDs.

COX selectivity is dose‑ and tissue‑dependent, so higher doses may reduce the relative COX‑2 preference.

Meloxicam has a long plasma half‑life of approximately 20 hours, which supports once‑daily dosing and steady symptom control for chronic osteoarthritis or rheumatoid arthritis.

It is hepatically metabolised and renally eliminated to varying degrees, so liver and kidney function influence dosing and safety monitoring.

Mechanistic implications for practice include starting low (7.5 mg), monitoring blood pressure and renal labs, and recognising platelet function and renal prostaglandin effects that can interact with other drugs.

COX Selectivity & Pharmacokinetics

Meloxicam belongs to ATC class M01AC06 — the oxicam group characterised by long half‑life and sustained anti‑inflammatory effect.

Preferential COX‑2 inhibition is modest compared with highly selective COX‑2 agents, so GI protection is not guaranteed.

Typical pharmacokinetics show a long duration of action, enabling once‑daily oral tablets or suspension and single‑dose IV use for acute moderate‑to‑severe pain.

Scope Of Approved And Off‑Label Use

Can meloxicam be used for everything that hurts?

Health Canada classifies meloxicam as a prescription NSAID with multiple formulations and DINs assigned per manufacturer and presentation.

Approved adult indications include osteoarthritis and rheumatoid arthritis for chronic once‑daily therapy.

IV meloxicam is approved for a single‑dose option for acute moderate‑to‑severe pain in adults where appropriate.

Pediatric use is addressed in some monographs for juvenile rheumatoid arthritis, with dosing from 0.125 mg/kg up to a 7.5 mg maximum for children aged two years and older — check the specific product monograph and DIN.

Common off‑label trends in Canadian practice include short‑term perioperative analgesia outside of situations where NSAIDs are contraindicated, and substitution for other NSAIDs when a once‑daily regimen is preferred.

Provincial formularies differ; many list meloxicam generics with specific criteria or prior authorisation for chronic coverage.

Notable Off‑Label Trends In Canadian Practice

Pharmacists commonly see substitution to meloxicam when patients want longer dosing intervals compared with ibuprofen or naproxen.

Short perioperative use is sometimes arranged in coordination with surgical teams, but post‑CABG use is contraindicated.

Always verify the product DIN and check payer rules before dispensing for chronic use.

Dosage Strategy

How should dosing be started and reviewed?

Standard adult oral dosing is 7.5–15 mg once daily for osteoarthritis and rheumatoid arthritis, with initiation at 7.5 mg and titration to 15 mg only if needed for symptom control.

IV meloxicam is used as a single 30 mg dose for acute moderate‑to‑severe pain in adults, not for ongoing therapy.

Pediatric dosing where permitted is 0.125 mg/kg once daily (maximum 7.5 mg) for children two years and older.

Elderly patients should start at the lowest effective dose — generally 7.5 mg daily — with early monitoring of renal function and blood pressure.

Renal impairment: avoid in severe renal failure and dialysis patients; use the lowest effective dose and monitor in mild‑to‑moderate impairment.

Hepatic impairment: use caution and consider dose reduction or avoidance in moderate to severe disease.

A practical titration plan is a 2–4 week trial at 7.5 mg then reassess pain relief and adverse effects before considering escalation.

Consider gastroprotection such as a PPI for patients with prior peptic ulcer disease or other high GI risk factors.

Special Populations (Elderly, Renal/Liver Impairment)

For patients aged 65 and over, prescribe the lowest effective dose and monitor renal function, liver enzymes and blood pressure.

Avoid meloxicam in severe hepatic or renal failure, and do not use it in patients on hemodialysis.

Safety Protocols

What precautions should patients and clinicians take?

Absolute contraindications include known hypersensitivity to meloxicam or other NSAIDs, history of NSAID‑induced asthma or urticaria, active or prior NSAID‑related GI bleeding or perforation, use immediately after CABG surgery, and severe hepatic or renal failure.

Common adverse effects are dyspepsia, nausea, diarrhoea, headache and rash.

Moderate‑to‑serious effects include peptic ulceration or GI bleeding, elevated liver enzymes, hypertension, oedema and renal impairment.

Post‑market reports from Canada and internationally reinforce renal risk in elderly patients on multiple medications and the persistent cardiovascular class signal.

Risk mitigation steps include using the lowest effective dose, limiting duration, considering PPI gastroprotection for high GI risk, and avoiding concomitant anticoagulant therapy where possible.

Baseline checks should include blood pressure, renal function (eGFR/creatinine), liver enzymes and haemoglobin for chronic users.

Report serious adverse events to Health Canada’s adverse reaction reporting system.

Contraindications (Canadian Advisories)

Do not use meloxicam in patients with known NSAID allergy or in cases of prior NSAID‑triggered asthma or urticaria.

Avoid for pain directly after coronary artery bypass graft surgery.

Severe hepatic or renal failure is exclusionary.

Adverse Effects (Post‑Market Reports)

Canadian post‑market surveillance highlighted renal adverse events among frail elderly on polypharmacy between 2022 and 2025.

Gastrointestinal bleeding and cardiovascular events remain observed class effects in long‑term users.

Interaction Mapping

Will meloxicam play badly with other medicines or food?

Meloxicam absorption is not markedly affected by food, but heavy alcohol increases GI bleeding risk and should be avoided while using NSAIDs.

Health Canada flags major drug interactions with anticoagulants such as warfarin and direct oral anticoagulants due to increased bleeding risk.

ACE inhibitors, ARBs and diuretics can interact to reduce renal function and increase the risk of acute kidney injury.

Concomitant use of other NSAIDs or aspirin increases GI and cardiovascular risk and is generally discouraged except for low‑dose aspirin for specific cardiovascular prophylaxis under medical supervision.

SSRIs and SNRIs increase gastrointestinal bleeding risk when combined with NSAIDs.

Meloxicam may reduce clearance of lithium and methotrexate, increasing toxicity risk, so monitor levels when co‑prescribed.

Meloxicam undergoes hepatic metabolism involving CYP pathways to varying degrees, so caution is advised with strong CYP inhibitors or inducers.

Food Interactions Common In Canadian Diet

Avoid heavy alcohol intake while taking meloxicam to reduce GI bleeding risk.

Normal meals do not require dose timing changes for meloxicam tablets or suspension.

Drug Combinations Flagged By Health Canada

Key flagged combinations include warfarin/DOACs, ACE inhibitors/ARBs, diuretics, other NSAIDs, SSRIs/SNRIs, lithium and methotrexate.

Pharmacists should perform medication reviews in community practice and flag high‑risk combinations for monitoring or alternative therapy.

Patient Experience Analysis

What do Canadian patients say about meloxicam?

Surveys and community pharmacy feedback show patients appreciate once‑daily dosing and sustained relief for chronic osteoarthritis and rheumatoid arthritis symptoms.

Patients often report reduced morning stiffness and the convenience of fewer daily doses compared with ibuprofen.

Common patient‑reported negatives include GI upset and concerns about blood pressure and kidney effects, especially among older adults.

Community pharmacies frequently substitute generics for cost savings and focus counselling on GI protection and the need for periodic bloodwork for chronic users.

Online forums show questions about switching from other NSAIDs and about provincial insurance coverage such as Ontario Drug Benefit, BC PharmaCare and RAMQ.

Forum And Community Pharmacy Trends

Pharmacists note that bilingual labelling and counselling in English and French improves understanding and adherence nationwide.

Documentation of counselling and local coverage details at the time of dispensing helps reduce barriers to access and ensures safer use.

Distribution And Pricing Landscape

Where can you buy meloxicam in Canada and what will it cost?

Meloxicam is widely available through national chains such as Shoppers Drug Mart, Rexall, Jean Coutu and London Drugs, and it is listed on many hospital formularies.

Multiple generics carry Health Canada DINs for tablets and suspension, and pack formats follow international norms.

Provincial formularies vary and may list meloxicam generics with specific benefit criteria or require prior authorisation for chronic coverage under programs such as Ontario Drug Benefit, BC PharmaCare and RAMQ.

Online licensed pharmacies in Canada sell meloxicam with a valid prescription and offer home delivery options.

In our online pharmacy, mobic is available without a prescription, with discreet delivery to Canada (English) in 5-14 days.

Cross‑border procurement from the United States may show price differences but carries regulatory and shipping risks, and the brand Mobic is discontinued in the US while generics remain available there.

Generic competition has reduced retail cost in Canada, but patients should confirm DIN and provincial coverage at the point of dispensing.

Online Pharmacy Availability & Provincial Restrictions

Licensed Canadian e‑pharmacies will dispense meloxicam by prescription and adhere to provincial dispensing rules.

Always verify the DIN and product monograph for formulation‑specific contraindications and paediatric limits before purchase.

Cross‑Border US Comparisons

US market differences include brand discontinuations such as Mobic, though generics are FDA‑approved.

Imported generics can vary in packaging and manufacturer, so pharmacists should verify authenticity and DIN equivalents when counselling patients.

Alternative Options

What are reasonable alternatives to meloxicam approved in Canada?

DIN‑approved alternatives include celecoxib (Celebrex) as a COX‑2 selective option, diclofenac (Voltaren generics) as a potent non‑selective NSAID, ibuprofen (Advil/Nurofen generics) for short‑term use, and piroxicam as another long‑acting oxicam.

Each option has pros and cons based on efficacy, dosing frequency, and safety profiles for cardiovascular, gastrointestinal and renal risks.

Pros And Cons Checklist

• Meloxicam: Once‑daily dosing and moderate COX‑2 preference make it convenient, but class CV/GI/renal risks persist.
• Celecoxib: Greater COX‑2 selectivity may reduce some GI ulcers in selected patients, but cardiovascular risk and higher cost are considerations.
• Diclofenac: Potent analgesia but associated with higher CV and GI risk.
• Ibuprofen: Good for acute pain, inexpensive, but needs multiple daily dosing for chronic symptoms.

Regulatory Status

How is meloxicam regulated in Canada?

Meloxicam products are prescription‑only and authorised via Health Canada New Drug Submissions or abbreviated submissions for generics.

Each marketed product carries a unique DIN that links to its approved monograph, indications and labelling details.

Health Canada requires bilingual labelling and mandates post‑market surveillance including adverse reaction reporting and periodic safety updates.

Provincial procurement and hospital sterile product handling rules apply for IV formulations.

Health Canada Approval Process

Product approval follows standard NDS/ANDS pathways and results in DIN assignment and public monograph details for clinicians and pharmacists.

DIN And Bilingual Labelling Rules

Products sold in Canada must have bilingual English/French labelling for consumer information and prescription packaging in most cases.

Consolidated FAQ

Can I Get Meloxicam Without A Prescription?

Meloxicam is prescription‑only in Canada according to Health Canada and product monographs, so a prescriber’s order is normally required.

Is Meloxicam Covered By Provincial Drug Plans?

Coverage varies by province; Ontario Drug Benefit, BC PharmaCare and RAMQ may list generics under criteria or require prior authorisation — check the provincial formulary and the DIN supplied at dispensing.

What If I’m On Blood Pressure Meds?

NSAIDs can raise blood pressure and blunt effects of ACE inhibitors or ARBs, so monitor blood pressure closely and consider alternative analgesics if hypertension is uncontrolled.

How Do I Switch From Another NSAID?

Switching does not always require a washout unless advised; pharmacists commonly recommend starting meloxicam at 7.5 mg for convenience while monitoring for efficacy and adverse effects.

Can I Use Meloxicam During Pregnancy Or Breastfeeding?

Avoid NSAIDs late in pregnancy due to risks to fetal cardiovascular system and labour; discuss risks with obstetric care providers.

Visual Guide — Infographics To Include

Dosage Visual: include icons for 7.5 mg and 15 mg tablets, 7.5 mg/5 mL suspension bottles and single‑use 30 mg IV vials with age/weight thresholds and a “start low” flag for patients aged 65 and older.

Provincial Coverage Map: a colour‑coded map showing likely formulary status and where prior authorisation may apply for each province.

Purchase Channels Flowchart: prescriber → community pharmacy (Shoppers/Rexall/Jean Coutu/London Drugs) → licensed online pharmacy → cross‑border cautions for US imports.

Safety Checklist Icons: monitor BP, renal labs, GI symptoms, and avoid post‑CABG use.

Storage And Transport

How should households store meloxicam?

Store tablets and oral suspension at controlled room temperature 20–25°C (68–77°F) away from moisture and light.

Shake oral suspension well before use and discard if appearance changes or after the expiration date.

IV formulations require sterile handling and manufacturer instructions for storage; check the product monograph and DIN specifics.

When travelling domestically, keep medicines in carry‑on luggage with prescription documentation and DIN reference to avoid customs delays for cross‑border travel.

Dispose of unused medication through provincial take‑back programs available at many chains such as Shoppers Drug Mart and London Drugs.

Guidelines For Proper Use

What will pharmacists tell you when dispensing meloxicam?

Pharmacists should verify indication and DIN, counsel on starting at 7.5 mg daily for most adults and elderly patients, and review the full medication list for interactions.

Document counselling and advise baseline and periodic monitoring of blood pressure, eGFR/creatinine and liver enzymes for chronic users.

Provincial formularies may require evidence of prior therapy such as acetaminophen or physiotherapy before long‑term coverage is authorised.

Avoid postoperative use after CABG and coordinate perioperative IV use with surgical and anesthesia teams.

Consider alternatives such as topical NSAIDs, celecoxib or acetaminophen where individual risk profiles make systemic NSAIDs less appropriate.

Encourage reporting of adverse events to Health Canada and maintain shared decision‑making with patients about ongoing therapy.

Delivery Across Canada (English)